Wells Fargo’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $66.9K | Buy |
110,500
+105,171
| +1,974% | +$79.1K | ﹤0.01% | 5323 |
|
|
2025
Q4 | $4.1K | Hold |
5,329
| – | – | ﹤0.01% | 6135 |
|
|
2025
Q3 | $5.38K | Hold |
5,329
| – | – | ﹤0.01% | 6065 |
|
|
2025
Q2 | $7.09K | Hold |
5,329
| – | – | ﹤0.01% | 6022 |
|
|
2025
Q1 | $6.34K | Buy |
5,329
+500
| +10% | +$711 | ﹤0.01% | 5982 |
|
|
2024
Q4 | $7.87K | Buy |
4,829
+100
| +2% | +$265 | ﹤0.01% | 5985 |
|
|
2024
Q3 | $18.1K | Buy |
4,729
+1,229
| +35% | +$4.1K | ﹤0.01% | 5665 |
|
|
2024
Q2 | $10.3K | Sell |
3,500
-6,989
| -67% | -$22.4K | ﹤0.01% | 5733 |
|
|
2024
Q1 | $41.5K | Buy |
10,489
+3,224
| +44% | +$16.6K | ﹤0.01% | 5333 |
|
|
2023
Q4 | $36.1K | Buy |
7,265
+1,298
| +22% | +$6.45K | ﹤0.01% | 5393 |
|
|
2023
Q3 | $30.1K | Sell |
5,967
-11,274
| -65% | -$61.8K | ﹤0.01% | 5430 |
|
|
2023
Q2 | $86.7K | Buy |
17,241
+11,841
| +219% | +$77.5K | ﹤0.01% | 5132 |
|
|
2023
Q1 | $33.2K | Sell |
5,400
-19,944
| -79% | -$163K | ﹤0.01% | 5389 |
|
|
2022
Q4 | $335K | Sell |
25,344
-370
| -1% | -$2.61K | ﹤0.01% | 3884 |
|
|
2022
Q3 | $77K | Buy |
25,714
+25,548
| +15,390% | +$108K | ﹤0.01% | 4746 |
|
|
2022
Q2 | $1K | Buy |
166
+14
| +9% | +$67 | ﹤0.01% | 6572 |
|
|
2022
Q1 | $1K | Hold |
152
| – | – | ﹤0.01% | 6842 |
|
|
2021
Q4 | $1K | Buy |
152
+5
| +3% | +$54 | ﹤0.01% | 7052 |
|
|
2021
Q3 | $2K | Buy |
147
+24
| +20% | +$299 | ﹤0.01% | 6585 |
|
|
2021
Q2 | $2K | Sell |
123
-1
| -0.8% | -$8 | ﹤0.01% | 6551 |
|
|
2021
Q1 | $1K | Sell |
124
-1
| -0.8% | -$4 | ﹤0.01% | 6752 |
|
|
2020
Q4 | $0 | Buy |
125
+51
| +69% | +$112 | ﹤0.01% | 6865 |
|
|
2020
Q3 | $0 | Hold |
74
| – | – | ﹤0.01% | 6736 |
|
|
2020
Q2 | $0 | Sell |
74
-1
| -1% | -$1 | ﹤0.01% | 6673 |
|
|
2020
Q1 | $0 | Buy |
75
+73
| +3,650% | +$126 | ﹤0.01% | 6634 |
|
|
2019
Q4 | $0 | Buy |
+2
| New | +$6 | ﹤0.01% | 6632 |
|
|
2018
Q4 | – | Sell |
-10
| Closed | – | – | 6554 |
|
|
2018
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 6518 |
|
|
2018
Q2 | $0 | Sell |
10
-5,678
| -100% | -$118K | ﹤0.01% | 6501 |
|
|
2018
Q1 | $134K | Buy |
5,688
+5,184
| +1,029% | +$1.39M | ﹤0.01% | 5178 |
|
|
2017
Q4 | $94K | Sell |
504
-358
| -42% | -$72K | ﹤0.01% | 5341 |
|
|
2017
Q3 | $186K | Buy |
862
+265
| +44% | +$54.8K | ﹤0.01% | 4966 |
|
|
2017
Q2 | $123K | Hold |
597
| – | – | ﹤0.01% | 5077 |
|
|
2017
Q1 | $109K | Buy |
597
+10
| +2% | +$1.98K | ﹤0.01% | 5158 |
|
|
2016
Q4 | $147K | Buy |
587
+260
| +80% | +$59.1K | ﹤0.01% | 4929 |
|
|
2016
Q3 | $68K | Buy |
327
+206
| +170% | +$40.8K | ﹤0.01% | 5143 |
|
|
2016
Q2 | $24K | Sell |
121
-1
| -0.8% | -$177 | ﹤0.01% | 5453 |
|
|
2016
Q1 | $22K | Hold |
122
| – | – | ﹤0.01% | 5486 |
|
|
2015
Q4 | $30K | Buy |
+122
| New | +$39.3K | ﹤0.01% | 5465 |
|
Other funds holding PDSB
VCM
VFT
IWA
AC
Wells Fargo's PDSB Position: Q1 2026 in Review
Wells Fargo increased its PDS Biotechnology (PDSB) stake by 1,974% in Q1 2026, buying an estimated $79.1K and bringing the position to 110,500 shares worth $66.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5323.
Wells Fargo first reported a position in PDSB in Q4 2015 and has held it in 38 quarters since. The position peaked at $335K in Q4 2022. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.
- Wells Fargo held 110,500 shares of PDS Biotechnology worth $66.9K as of Q1 2026.
- Wells Fargo bought 105,171 PDS Biotechnology shares in Q1 2026, an estimated $79.1K.
- PDS Biotechnology made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5323 holding.
- Wells Fargo first reported a position in PDS Biotechnology in Q4 2015 and has held it in 38 quarters since.
- Wells Fargo's PDS Biotechnology position peaked at $335K in Q4 2022.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.